These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 21610041)
1. Cardiovascular risk during androgen deprivation therapy for prostate cancer. Jones TH BMJ; 2011 May; 342():d3105. PubMed ID: 21610041 [No Abstract] [Full Text] [Related]
2. Long term androgen deprivation therapy in prostate cancer. Ockrim JL; Abel PD BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586 [No Abstract] [Full Text] [Related]
3. I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried? Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):8. PubMed ID: 20518140 [No Abstract] [Full Text] [Related]
4. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone. Aragon-Ching JB J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519 [No Abstract] [Full Text] [Related]
5. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
6. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Galvão DA; Newton RU; Taaffe DR; Spry N Nat Clin Pract Urol; 2008 Jun; 5(6):306-7. PubMed ID: 18431358 [No Abstract] [Full Text] [Related]
11. [Androgen deprivation and cardiovascular risk in prostate cancer treatment]. Leclercq C; Bouchot O; Azzouzi AR; Joly F; Miaadi N; Pfister C; Vincendeau S; de Crevoisier R Prog Urol; 2012 Sep; 22 Suppl 2():S48-54. PubMed ID: 23098790 [TBL] [Abstract][Full Text] [Related]
12. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. Ross RW; Small EJ J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Collier A; Ghosh S; McGlynn B; Hollins G Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430 [TBL] [Abstract][Full Text] [Related]
15. Metabolic and cardiovascular effects of androgen deprivation therapy. Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614 [TBL] [Abstract][Full Text] [Related]
16. Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency. Kim J; Vaid M; Tyldesley S; Woods R; Pickles T Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):742-50. PubMed ID: 20630664 [TBL] [Abstract][Full Text] [Related]
17. Researchers probe consequences of androgen deprivation for prostate cancer. Friedrich MJ JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787 [No Abstract] [Full Text] [Related]
18. Cardiovascular effects of androgen depletion and replacement therapy. Pinthus JH; Trachtenberg J; Klotz L Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164 [No Abstract] [Full Text] [Related]
19. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Hamilton EJ; Gianatti E; Strauss BJ; Wentworth J; Lim-Joon D; Bolton D; Zajac JD; Grossmann M Clin Endocrinol (Oxf); 2011 Mar; 74(3):377-83. PubMed ID: 21118287 [TBL] [Abstract][Full Text] [Related]
20. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved. Azvolinsky A J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000 [No Abstract] [Full Text] [Related] [Next] [New Search]